RxDoctor Payments DataLook up a doctor →

Salvatore Sciurba, PA

Physician Assistant · Middletown, NJNPI 1093765307

Payments from drug & device makers

$24,731in general payments, 2019–2025

Across 1,530 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$3K
  • Almirall LLC$3K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • Novartis$1K
  • Incyte Corporation$1K
  • plus $12K from 22 others

What the payments were for

  • Consulting fees$1,0004%
  • Speaking & faculty fees$1,9258%
  • Food & beverage$21,04285%
  • Education$7633%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,731 in reported general payments places this provider in the 95th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$276,137
Medicare patients
1,029
Services billed
4,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab27$181,138
TremfyaGuselkumab11$139,081
Dupixent SyringeDupilumab31$110,189
OtezlaApremilast17$81,699
Dupixent PenDupilumab16$59,235
OpzeluraRuxolitinib Phosphate16$30,811
Fluorouracil142$9,380
Tacrolimus51$3,754
Clobetasol Propionate63$3,461
Pimecrolimus13$3,378
Doxycycline Hyclate116$2,122
Fluocinonide51$1,971
Mometasone Furoate126$1,675
Clindamycin Phosphate38$1,662
Tretinoin40$1,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,807$139,08111 claims
AmgenOtezla$1,170$81,69917 claims
Incyte CorporationOpzelura$1,290$30,81116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Middletown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →